Free Trial

Palisade Bio Q4 2024 Earnings Report

Palisade Bio logo
$0.66 +0.02 (+3.26%)
As of 02:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Palisade Bio EPS Results

Actual EPS
-$0.69
Consensus EPS
-$2.39
Beat/Miss
Beat by +$1.70
One Year Ago EPS
N/A

Palisade Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Palisade Bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Palisade Bio Earnings Headlines

Maxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
See More Palisade Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email.

About Palisade Bio

Palisade Bio (NASDAQ:PALI), a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

View Palisade Bio Profile

More Earnings Resources from MarketBeat